Nasdaq · CIK 0001088856 · PHARMACEUTICAL PREPARATIONS
CORCEPT THERAPEUTICS INC
CORT chart by TradingView
PRICE HISTORY
LIVE · NASDAQCORT chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.8B
- EBITDA
- $0.0B
- FREE CASH FLOW
- $0.1B
- EPS
- $0.83
- GROSS MARGIN
- 98.30%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
186.5x
+11%11.7x186.5x
⤢
P / SALES (TTM)
12.4x
+19%4.3x20.0x
⤢
P / BOOK
14.6x
-40%3.5x28.1x
⤢
EV / EBITDA (TTM)
—
-47%55.4x105.1x
⤢
EV / REVENUE (TTM)
—
+30%9.9x14.0x
⤢
FCF YIELD (TTM)
1.04%
-1.3pp1.04%9.97%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.3B
+1079%⤢
EBITDA (DERIVED)
$0.0B
+1263%⤢
NET INCOME
$0.0B
+1563%⤢
EPS (DILUTED)
$0.36
+1535%⤢
REVENUE GROWTH YOY
31.74%
-32.1pp-14.81%123.76%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
12.11%
-28.6pp-10.29%68.99%
⤢
RETURN ON CAPITAL
—
-148.4pp57.79%213.67%
⤢
RETURN ON EQUITY (TTM)
7.82%
-6.6pp7.42%67.61%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN98.41%
OPERATING MARGIN16.12%
NET MARGIN16.78%
FCF MARGIN12.11%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.0B
+251%⤢
STOCK-BASED COMP
$0.0B
+1507%⤢
CAPITAL EXPENDITURE
$0.0B
+2709%⤢
SHARES OUTSTANDING
0.12B
+2%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.1B
+132%⤢
TOTAL DEBT
—
-76%⤢
DEBT / EBITDA (TTM)
—
-93%0.2x2.7x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 76.40%INSIDERS 11.46%OTHER / RETAIL 12.14%524 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 11.24% | 12.2M | $1.35B | +0.7% |
| Ingalls & Snyder LLC | 7.04% | 7.6M | $842.8M | +5.8% |
| Renaissance Technologies, LLC | 5.26% | 5.7M | $629.5M | -1.3% |
| Vanguard Portfolio Management LLC | 4.46% | 4.8M | $534.0M | NEW |
| Vanguard Capital Management LLC | 3.77% | 4.1M | $451.6M | NEW |
| Parallel Advisors, LLC | 3.67% | 4.0M | $438.9M | -0.4% |
| State Street Corporation | 2.96% | 3.2M | $354.6M | +7.2% |
| FMR, LLC | 2.95% | 3.2M | $353.4M | +32.1% |
| Geode Capital Management, LLC | 2.51% | 2.7M | $300.6M | +1.7% |
| First Trust Advisors LP | 2.01% | 2.2M | $240.7M | +213.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.